Association of baseline dyslipidemia with stroke recurrence within five-years after ischemic stroke

International Journal of Stroke

Volumn 9, Issue A100, 2014, Pages 119-126

  Kumral, Emre ^a   Evyapan, Dilek ^a   Gökçay, Figen ^a   Karaman, Bedriye ^a   Orman, Mehmet ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cardioembolic stroke; Large artery disease; Lipids; Small artery disease; Stroke recurrence

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; DANAPAROID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERURICEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; SMOKING; STROKE PATIENT; SUBARACHNOID HEMORRHAGE; SURVIVAL RATE; BLOOD; BLOOD PRESSURE; CLASSIFICATION; COMPLICATION; DYSLIPIDEMIAS; ELECTROCARDIOGRAPHY; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; PHYSIOLOGY; RECURRENT DISEASE; REGISTER; RISK FACTOR; STROKE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; DYSLIPIDEMIAS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; REGISTRIES; RISK FACTORS; STROKE;

EID: 84912017030     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12341     Document Type: Article

References (38)

1. Cholesterol, diastolic blood pressure, and stroke: 13, 000 strokes in 450, 000 people in 45 prospective cohorts: prospective studies collaboration. Lancet 1995; 346:1647-1653.
2. Horenstein RB, Smith DE, Mosca L. Cholesterol predicts stroke mortality in the Women's Pooling Project. Stroke 2002; 33:1863-1868.
3. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350, 977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904-910.
4. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994; 309:11-15.
5. Piechowski-Jozwiak B, Bogousslavsky J. Cholesterol as a risk factor for stroke: the fugitive? Stroke 2004; 35:1523-1524.
6. Sacco RL, Benson RT, Kargman DE etal. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001; 285:2729-2735.
7. Shahar E, Chambless LE, Rosamond WD etal. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003; 34:623-631.
8. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Stroke 2009; 40:e622-623.
9. Nassief A, Marsh JD. Statin therapy for stroke prevention. Stroke 2008; 39:1042-1048.
10. Sacco RL, Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989; 20:983-989.
11. Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31:1062-1068.
12. Adams HP Jr, Bendixen BH, Kappelle LJ etal. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24:35-41.
13. Kumral E, Ozkaya B, Sagduyu A, Sirin H, Vardarli E, Pehlivan M. The Ege Stroke Registry: a hospital-based study in the Aegean Region, Izmir, Turkey. Cerebrovasc Dis 1998; 8:278-288.
14. Stroke - 1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989; 20:1407-1431.
15. Smith EE, Abdullah AR, Amirfarzan H, Schwamm LH. Serum lipid profile on admission for ischemic stroke: failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. Neurology 2007; 68:660-665.
16. SPSS Inc. An IBM Company Headquarters, 233 S. Wacker Drive, 11th floor Chicago, Illinois. 2012.
17. Hardie K, Jamrozik K, Hankey GJ, Broadhurst RJ, Anderson C. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc Dis 2005; 19:179-185.
18. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994; 44:626-634.
19. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66:641-646.
20. Mohan KM, Crichton SL, Grieve AP, Rudd AG, Wolfe CD, Heuschmann PU. Frequency and predictors for the risk of stroke recurrence up to 10 years after stroke: the South London Stroke Register. J Neurol Neurosurg Psych 2009; 80:1012-1018.
21. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology 1998; 50:208-216.
22. Modrego PJ, Mainar R, Turull L. Recurrence and survival after first-ever stroke in the area of Bajo Aragon, Spain. A prospective cohort study. J Neurol Sci 2004; 224:49-55.
23. Hata J, Tanizaki Y, Kiyohara Y etal. Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study. J Neurol Neurosurg Psych 2005; 76:368-372.
24. Azarpazhooh MR, Nicol MB, Donnan GA etal. Patterns of stroke recurrence according to subtype of first stroke event: the North East Melbourne Stroke Incidence Study (NEMESIS). Int J Stroke 2008; 3:158-164.
25. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, Anderson C. Ten-year risk of first recurrent stroke and disability after first-ever stroke in the Perth Community Stroke Study. Stroke 2004; 35:731-735.
26. Heart Protection Collaborative Study Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20, 536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
27. Shepherd J, Blauw GJ, Murphy MB etal. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630.
28. Sever PS, Dahlof B, Poulter NR etal. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361:1149-1158.
29. Amarenco P, Benavente O, Goldstein LB etal.; on behalf of the SPARCL Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40:1405-1409.
30. Yilong W, Jie X, Xingquan Z, David W, Chunxue W, Liping L. Association of hypertension with stroke recurrence depends on ischemic stroke subtype. Stroke 2013; 44:1232-1237.
31. Hadaegh F, Mohebi R, Cheraghi L etal. Do different metabolic syndrome definitions predict cerebrovascular events and coronary heart disease independent of their components?: 9 years follow-up of the tehran lipid and glucose study. Stroke 2012; 43:1669-1671.
32. van der Meer IM, Iglesias del Sol A, Hak AE, Bots ML, Hofman A, Witteman JC. Risk factors for progression of atherosclerosis measured at multiple sites in the arterial tree: the Rotterdam Study. Stroke 2003; 34:2374-2379.
33. Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25:333-337.
34. Xu G, Liu X, Wu W, Zhang R, Yin Q. Recurrence after ischemic stroke in chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovasc Dis 2007; 23:117-120.
35. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62:569-573.
36. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31:1062-1068.
37. Schulz UG, Rothwell PM. Differences in vascular risk factors between etiological subtypes of ischemic stroke: importance of population-based studies. Stroke 2003; 34:2050-2059.
38. Amarenco P, Goldstein LB, Sillesen H etal.; on behalf of the SPARCL Investigators. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2010; 41:426-430.